HBW
FOLD

Hazlett, Burt & Watson’s Amicus Therapeutics FOLD Stock Holding History

Hazlett, Burt & Watson’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,569
Closed -$23K – 915
2026
Q1 		$23K Hold
1,569
– – 0.01% 564
2025
Q4 		$22K Hold
1,569
– – 0.01% 586
2025
Q3 		$12K Hold
1,569
– – ﹤0.01% 635
2025
Q2 		$9K Hold
1,569
– – ﹤0.01% 600
2025
Q1 		$13K Hold
1,569
– – 0.01% 541
2024
Q4 		$15K Sell
1,569
-1,000
-39% -$10.4K 0.01% 494
2024
Q3 		$28K Buy
2,569
+1,569
+157% +$17.1K 0.01% 427
2024
Q2 		$10K Hold
1,000
– – 0.01% 523
2024
Q1 		$12K Hold
1,000
– – 0.01% 497
2023
Q4 		$14K Hold
1,000
– – 0.01% 459
2023
Q3 		$12K Hold
1,000
– – 0.01% 478
2023
Q2 		$13K Hold
1,000
– – 0.01% 455
2023
Q1 		$11K Hold
1,000
– – 0.01% 439
2022
Q4 		$12K Hold
1,000
– – 0.01% 440
2022
Q3 		$10K Hold
1,000
– – 0.01% 452
2022
Q2 		$11K Hold
1,000
– – 0.01% 444
2022
Q1 		$9K Buy
+1,000
New +$9.38K 0.01% 479

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Hazlett, Burt & Watson's FOLD Position: Q2 2026 in Review

Hazlett, Burt & Watson sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,569 shares — an estimated $23K sold.

Hazlett, Burt & Watson first reported a position in FOLD in Q1 2022 and held it in 17 quarters. The position peaked at $28K in Q3 2024. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Hazlett, Burt & Watson reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 1,569 Amicus Therapeutics shares in Q2 2026, an estimated $23K.
  • Hazlett, Burt & Watson first reported a position in Amicus Therapeutics in Q1 2022 and held it in 17 quarters.
  • Hazlett, Burt & Watson's Amicus Therapeutics position peaked at $28K in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.